Pallas Health vs Sunlight: Price, meds, and clinician model

Pallas Health vs Sunlight: quick verdict — Pallas lets a US-licensed clinician choose between FDA-approved brand pens and patient-specific compounded semaglutide or tirzepatide, with compounded semaglutide starting at $139 first month; Sunlight emphasizes lower entry pricing, advertising personalized GLP-1 plans from $88/mo and a same price forever promise. Early verdict: choose Pallas for clinician access to both brand and compounded options, choose Sunlight if a lower starting monthly price and a fixed price promise are decisive.

Explore Pallas Health plans starting at $139

How the two providers differ at a glance

This comparison focuses on the most distinctive supported differences: pricing structure and entry cost, medication options and compounded status, price guarantees and renewal cadence, shipping and delivery speed, and clinician review and visit requirements. The article compares Pallas Health and Sunlight directly on each point using only supplied facts.

Comparison table

Pricing structure and entry cost

Pallas Health lists compounded semaglutide at $139 for the first month and notes that compounded semaglutide renews at $597 every 12 weeks, a $199 monthly average. Compounded tirzepatide starts at $179 first month and renews at $897 every 12 weeks, a $299 monthly average. Pallas also lists cash-pay brand-name prices for Wegovy, Zepbound, Ozempic and Mounjaro on its site. Sunlight advertises personalized GLP-1 plans from $88/mo and promotes as low as $88 plus promos. Sunlight further emphasizes a same price forever promise and no monthly membership. If low entry pricing matters, Sunlight advertises a lower starting monthly figure, while Pallas advertises a low first-month price for compounded plans but a different renewal cadence.

See Sunlight plans from $88/mo

Medication options and compounded medications

Both providers mention clinician involvement, but their medication offerings differ in emphasis. Pallas explicitly offers a clinician choice between FDA-approved brand-name pens and clinician-personalized compounded semaglutide or tirzepatide prepared in the USA when a brand medication is not the right fit. Pallas states that compounded medications are not FDA-approved and are prepared by US-licensed compounding pharmacies. Sunlight presents injections and oral options and calls its plans personalized GLP-1. The captured evidence for Sunlight notes that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable. If having a clinician decide between brand and compounded options is a priority, the supplied evidence names Pallas for that workflow.

Compare Pallas medication choices and clinician review

Price guarantees, renewals and fine print

Sunlight’s captured claims emphasize a same price forever promise and no price increases ever. Pallas discloses that compounded plans use a 12 week renewal cadence and that first-month pricing differs from renewal pricing, and that plan prices are by medication rather than by milligram so titration does not raise the plan price. Pallas also notes cash-pay only and that FSA or HSA use may require a Letter of Medical Necessity. For readers focused on predictable renewals or a fixed monthly rate, Sunlight’s same price forever claim is a distinguishing point in the supplied evidence, while Pallas provides details about its 12 week renewal rhythm and pricing by medication.

Shipping, visit requirements, and clinician access

Pallas advertises free expedited and discreet shipping on every plan and states a US-licensed clinician reviews eligibility. Pallas is 100 percent online and asynchronous in most states but requires a video visit in seven states plus Washington, D.C. Sunlight advertises fast and free shipping, free discreet 2-day shipping in captured evidence, and a 100 percent online medical visit with prescription and telehealth included. Both providers emphasize online clinician review; Pallas specifically notes eligibility is determined by a US-licensed clinician and that compounded medications are prepared by compounding pharmacies rather than by Pallas directly.

Check Sunlight eligibility and shipping

What to choose based on the evidence

Summing up Pallas Health vs Sunlight: Pallas stands out for clinician-directed access to both FDA-approved brand pens and US-compounded semaglutide or tirzepatide, with compounded semaglutide at $139 first month and a 12 week renewal cadence. Sunlight stands out for a lower advertised entry price from $88/mo and an advertised same price forever promise plus fast 1 to 2 day shipping. Use the primary keyword Pallas Health vs Sunlight to remember this contrast: clinician-led brand or compounded choice and 12 week pricing from Pallas, versus lower starting monthly price and fixed price promise from Sunlight.

Choose Pallas Health if you want a US-licensed clinician to weigh brand-name pens and clinician-personalized compounded semaglutide or tirzepatide as captured in the evidence, with compounded semaglutide starting at $139 first month and free expedited shipping.

Choose Sunlight if a lower advertised entry price and a same price forever promise with fast 1 to 2 day shipping are the deciding factors according to the captured evidence.